New preclinical data validate anti-tumor efficacy and intracranial activity of the drug candidate Bridge submitted an IND application to the U.S. Food and Drug Administration in March, and expects to initiate the first-in-human study of BBT-207 this year SEONGNAM, South Korea and CAMBRIDGE, Mass., April 19, 2023 /PRNewswire/ Bridge Biotherapeutics (KQ288330), a clinical-stage biotech company based in.
Bridge Biotherapeutics Releases Updated Preclinical Data for BBT-207 at the AACR Annual Meeting streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Jurors this week had to sift through five weeks of testimony regarding a slain East Auckland grandmother's unusually fraught business and personal life. Cr